Evotec OAI and Oxagen in drug discovery alliance
Evotec OAI and Oxagen, a biopharmaceutical company based near Oxford in the UK, have entered into an alliance to identify chemical compounds inter-acting with one of Oxagen's lead drug targets.
Evotec OAI and Oxagen, a biopharmaceutical company based near Oxford in the UK, have entered into an alliance to identify chemical compounds inter-acting with one of Oxagen's lead drug targets.
Evotec OAI will apply its fully integrated drug discovery process know-how to express the target of interest, develop Ca2+ flux assays, screen the target against its corporate library of drug-like small molecule com-pounds and provide profiling services to Oxagen. The contract also includes an option for Evotec OAI to provide medicinal chemistry services where Evotec OAI chemists would design and synthesise focussed libraries based on the templates identified in screening biased towards Oxagen's target
Dr Mark Payton, ceo of Oxagen, said: 'This marks Oxagen's first steps into developing proprietary drugs based on targets identified through our genetic capabilities. We are looking forward to the collaboration with Evotec OAI as we believe its extensive drug discovery capabilities will greatly support us in efficiently progressing our target discoveries through functional biology and on into chemistry.'